旗濱集團(601636.SH):控股孫公司25噸中性硼硅藥用玻璃素管生產線點火
格隆匯1月28日丨旗濱集團(601636.SH)公佈2021年1月28日,公司控股孫公司湖南旗濱醫藥材料科技有限公司第一期25噸中性硼硅藥用玻璃素管項目工程建設基本結束,並於當日舉行了點火烤窯儀式。
烤窯結束後將進入設備聯合調試和試產階段。本項目的產品包括無色和琥珀色玻管,可用於生產注射器、卡式瓶和筆式系統、安瓿瓶以及西林瓶等的藥品包裝。中性硼硅藥用玻璃適宜於盛裝生物製品、血液製品、凍乾製劑、疫苗等附加值較高的藥品和PH值較高的特殊藥品,在耐水性、抗冷熱衝擊性、耐酸鹼及抗侵蝕性等多項重要指標方面有較強的優勢,能充分滿足市場對高端藥用玻璃的需要。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.